Only recently have primary targets of existing neuropsychiatric drugs, such as the dopamine 2 receptor (DRD2) or glutamate receptor subunits (GRM3, GRIN2A, GRIA1) in schizophrenia, been linked to genetic risk of disease at the population level through large-scale genome-wide association studies (GWAS; see Glossary)10. The gene discussed is GRM3; the disease is schizophrenia.